• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of pharmacy practice >The Impact of Cirrhosis and Prescription Medications on QTc Interval Before and After Liver Transplantation
【24h】

The Impact of Cirrhosis and Prescription Medications on QTc Interval Before and After Liver Transplantation

机译：肝硬化和处方药对肝移植前后QTC间隔的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Higher rates of corrected QT (QTc) prolongation have been reported in patients with cirrhosis. The impact of liver transplantation and prescription medications on the natural history of QTc prolongation has yet to be well characterized. Methods: This was a single-center review of patients receiving (group 1) or listed for (group 2) a liver transplant during 2014. Patients in group 1 were followed prospectively from the date of transplantation to assess rates of QTc normalization posttransplant. In group 2, patients were evaluated from the date of listing up until December 2015 to assess the prevalence of QTc prolongation among liver transplant candidates. Results: In group 1, 22 (75.9%) patients with QTc intervals >460 milliseconds at the time of transplant established normal baseline QTc intervals following transplantation. The median time to this QTc normalization was 17 days. In group 2, 30 (16.9%) patients had at least 1 documented QTc interval >500 milliseconds with prevalence rates of 42.9%, 19.0%, and 10.2% in patients with natural model of end-stage liver disease scores of >30, 16 to 30, and <16, respectively ( P < .01). Overall, 49.4% of patients in group 1 and 47.5% of patients in group 2 were prescribed QTc prolonging medications. Conclusion: QTc prolongation will resolve following transplantation in the majority of patients and generally occurs within the first several weeks. Among the listed liver transplant candidates, higher rates of clinically significant QTc prolongation may be observed in patients with more severe underlying cirrhosis. QTc prolonging medications are commonly prescribed in this population and warrant monitoring following initiation.
机译：背景：肝硬化患者报道了较高的矫正QT（QTC）延长率。肝移植和处方药对QTC延长自然病史的影响尚未得到很好的特征。方法：这是对接受（第1组）或（第2组）患者的单中心评价（第2组）2014年肝脏移植患者。第1次患者从移植日期前瞻性，以评估QTC标准化后普拉特的催化剂。在第2组中，患者自2015年12月至12月的日期评估，以评估肝移植候选人QTC延长的患病率。结果：在第1,22族（75.9％）QTC间隔患者>移植后的QTC间隔患者> 460毫秒建立了正常基线QTC间隔后移植。这个QTC标准化的中位时间为17天。在第2组中，30名（16.9％）患者至少有1个记录的QTC间隔> 500毫秒，患者患有42.9％，19.0％和10.2％的患者患者，终末期肝病分数> 30,16分别为30和<16（p <.01）。总体而言，第1次和第2组患者的49.4％的患者进行了规定的QTC延长药物。结论：QTC延长将在大多数患者移植后解决，并且通常在前几周内发生。在列出的肝移植候选者中，可以在更严重的肝硬化患者中观察到更高的临床显着QTC延长率。 QTC延长药物通常在该人口中规定，并在启动后进行监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号